Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era.
暂无分享,去创建一个
M. Pencina | N. Kleiman | D. Cohen | S. Nathan | S. Marso | M. Keyes | W. Marquardt | R. Piana | Gaurav Dhar | S. Rao | J. Lopez | Salim Shammo | John J. Lopez | D. Cohen
[1] M. Pencina,et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. , 2009, JACC. Cardiovascular interventions.
[2] Sunil V. Rao,et al. Strategies to reduce bleeding among patients with ischemic heart disease treated with antiplatelet therapies. , 2009, American Journal of Cardiology.
[3] R. Wilensky,et al. Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute–Sponsored, Multicenter 1985–1986 PTCA and 1997–2006 Dynamic Registries , 2008, Circulation. Cardiovascular interventions.
[4] E. Vicaut,et al. Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. , 2008, International journal of cardiology.
[5] A. Kastrati,et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.
[6] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[7] K. Eagle,et al. Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications. , 2007, The American journal of cardiology.
[8] H. White,et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.
[9] J. Ware,et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial , 2007, The Lancet.
[10] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[11] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[12] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[13] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[14] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[15] R. Califf,et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.
[16] David J Cohen,et al. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. , 2005, American heart journal.
[17] A. Kastrati,et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. , 2005, European heart journal.
[18] I. Iakovou,et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.
[19] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[20] Charles L. Brown,et al. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.
[21] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[22] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[23] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[24] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[25] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[26] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.
[27] A. Kastrati,et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.
[28] W. Laskey,et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. , 2001, The American journal of cardiology.
[29] R. Califf,et al. Post-procedure heparin: boon or burden? , 1998, American heart journal.
[30] B. Meier,et al. Prolonged heparin after uncomplicated coronary interventions: A prospective, randomized trial , 1998 .
[31] E. Braunwald,et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). , 1997, The American journal of cardiology.
[32] W. O’Neill,et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. , 1994, Journal of the American College of Cardiology.
[33] P. Fail,et al. Subcutaneous heparin in postangioplasty management: comparative trial with intravenous heparin. , 1993, American heart journal.
[34] S. Ellis,et al. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. , 1989, American heart journal.
[35] J. Ioannidis,et al. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. , 2003, Journal of the American College of Cardiology.